P1713: VENETOCLAX IN COMBINATION WITH OBINUTUZUMAB IN FIRST LINE CHRONIC LYMPHOCYTIC LEUKEMIA IN ARGENTINA: A COST-EFFECTIVENESS ANALYSIS

• D. Kanevsky,
• J. Elgart,
• M. Zerga,
• M. Glancszpigel,
• P. Morisset

Affiliations

D. Kanevsky

1 Market Access, Abbvie, Buenos Aires

J. Elgart

2 CENEXA, Center of Experimental and Applied Endocrinology (UNLP-CONICET, La Plata

M. Zerga

3 Instituto de Oncología “Angel Roffo”. UBA.

M. Glancszpigel

4 3eff, Buenos Aires, Argentina

P. Morisset

5 Abbvie, Chicago, United States of America